The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 39)
Improved Biomarkers & Clinical Outcome Measures, 2016
Prior to the appearance of classic movement abnormalities like tremor and slowness, those with Parkinson's suffer from non-motor symptoms, such as altered function of the gastrointestinal tract, depression and changes in the sense of smell. The secretion of specific proteins into tears may be regulated by similar changes in nerve function that are seen in these other affected syste...
Researchers: Sarah F. Hamm-Alvarez, PhD
Therapeutic Pipeline Program, 2016
Anxiety disorders occur in up to 35 percent of people with Parkinson's disease and can have a negative impact on gait, involuntary movements, motor fluctuations and quality of life. With this study we intend to develop a treatment module for anxiety in patients with Parkinson's disease based on cognitive behavioral therapy methods and assess its efficacy in reducing anxiety symptom...
Researchers: Albert F. G. Leentjens, MD, PhD
Research Grant, 2016
Depression is a common non-motor symptom associated with Parkinson's disease (PD), and impulse control disorders (ICDs) are behaviors that may arise with use of certain PD medications. (Read more about ICDs in Parkinson's.) Both depression and ICDs can significantly affect the quality of life for people with PD and their care partners. It is unknown what changes in the brain cause...
Therapeutic Pipeline Program, 2015
There is a critical need for treatments that address depression and barriers to care among the approximately 5 million people living with Parkinson's disease (PD) worldwide. The purpose of this research is to test a new treatment (Telephone-Administered Cognitive Behavioral Therapy or T-CBT) for depression in PD. The treatment does not involve medication but teac...
Researchers: Roseanne D. Dobkin, PhD
Research Grant, 2015
Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson's Disease Supplement
STATegics has discovered small molecules that selectively activate the tissue-protective erythropoietin (EPO) receptor, but not the EPO receptor that plays a role in red blood cell production. In previous studies, the lead compound demonstrated potent neuroprotective effects, favorable safety profile and efficacy in protecting dopaminergic neurons in models of Pa...